919200-71-8

Basic information

• Product Name: 4-Pyrimidinamine, 2-chloro-N-(3-chloro-4-fluorophenyl)-
• Synonyms: (2-chloropyrimidin-4-yl)(3-chloro-4-fluorophenyl)amine;4-Pyrimidinamine,2-chloro-N-(3-chloro-4-fluorophenyl)
• CAS NO: 919200-71-8
• Molecular Formula: C10H6Cl2FN3
• Molecular Weight: 258.082
• Mol File: 919200-71-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-Pyrimidinamine, 2-chloro-N-(3-chloro-4-fluorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyrimidinamine, 2-chloro-N-(3-chloro-4-fluorophenyl)-(919200-71-8)
• EPA Substance Registry System: 4-Pyrimidinamine, 2-chloro-N-(3-chloro-4-fluorophenyl)-(919200-71-8)

Safety Data

• Hazardous Substances Data: 919200-71-8(Hazardous Substances Data)

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 367-21-5 3-chloro-4-fluorophenylamine 

Downstream Products

• 1050499-84-7 N₄-(3-chloro-4-fluorophenyl)-N₂-(4-morpholinophenyl)pyrimidine-2,4-diamine 
• 1050499-85-8 N₄-(3-chloro-4-fluorophenyl)-N₂-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,4-diamine 
• 1050499-83-6 N₄-(3-chloro-4-fluorophenyl)-N₂-(4-fluorophenyl)pyrimidine-2,4-diamine 
• 1050499-94-9 N₄-(3-chloro-4-fluorophenyl)-N₂-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)pyrimidine-2,4-diamine 
• 1050499-90-5 N₄-(3-chloro-4-fluorophenyl)-N₂-(4-(trifluoromethyl)phenyl)pyrimidine-2,4-diamine 
• 1050499-87-0 N₄-(3-chloro-4-fluorophenyl)-N₂-(6-(trifluoromethyl)pyridin-3-yl)pyrimidine-2,4-diamine 
• 1050499-95-0 N₄-(3-chloro-4-fluorophenyl)-N₂-(3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,4-diamine 

Relevant articles and documents

Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimer's disease

Development of multitargeted ligands have demonstrated remarkable efficiency as potential therapeutics for Alzheimer's disease (AD). Herein, we reported a new series of deoxyvasicinone analogues as dual inhibitor of acetylcholinesterase (AChE) and tau aggregation that function as multitargeted ligands for AD. All the multitargeted ligands 11(a-j) and 15(a-g) were designed, synthesized, and validated by 1HNMR, 13CNMR and mass spectrometry. All the synthesized compounds 11(a-j) and 15(a-g) were screened for their ability to inhibit AChE, BACE1, amyloid fibrillation, α-syn aggregation, and tau aggregation. All the screened compounds possessed weak inhibition of BACE-1, Aβ42 and α-syn aggregation. However, several compounds were identified as potential hits in the AChE inhibitory screening assay and cellular tau aggregation screening. Among all compounds, 11f remarkably inhibited AChE activity and cellular tau oligomerization at single-dose screening (10 μM). Moreover, 11f displayed a half-maximal inhibitory concentration (IC50) value of 0.91 ± 0.05 μM and half-maximal effective concentration (EC50) value of 3.83 ± 0.51 μM for the inhibition of AChE and cellular tau oligomerization, respectively. In addition, the neuroprotective effect of 11f was determined in tau-expressing SH-SY5Y cells incubated with Aβ oligomers. These findings highlighted the potential of 11f to function as a multifunctional ligand for the development of promising anti-AD drugs.

PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS

Pyrimidine-2,4-diamines derivatives having activity as JAK2 kinase inhibitors are disclosed, as well as pharmaceutical compositions and methods for using the same in the treatment of cancer and other JAK2 kinase-associated conditions.